Copyright
©The Author(s) 2017.
World J Diabetes. Jul 15, 2017; 8(7): 311-316
Published online Jul 15, 2017. doi: 10.4239/wjd.v8.i7.311
Published online Jul 15, 2017. doi: 10.4239/wjd.v8.i7.311
Table 2 Proprotein convertase subtilisin/kexin type 9 inhibitors and diabetes mellitus: Results of the mendelian randomization studies
PCSK9 variants | Decrease in serum LDL cholesterol | Odds ratio for type 2 diabetes mellitus |
rs 11591147[15] | 1 mmol/L (38.4 mg/dL) | 1.19 (95%CI: 1.02-1.38) |
14 independent variants[16] (rs 11583680, rs 11591147, rs 2479109, rs 11206510) | 1 mmol/L (38.4 mg/dL) | 1.29 (95%CI: 1.11-1.50) |
2Genetic score[17] | 10 mg/dL | 1.11 (95%CI: 1.04-1.19) |
- Citation: Filippatos TD, Filippas-Ntekouan S, Pappa E, Panagiotopoulou T, Tsimihodimos V, Elisaf MS. PCSK9 and carbohydrate metabolism: A double-edged sword. World J Diabetes 2017; 8(7): 311-316
- URL: https://www.wjgnet.com/1948-9358/full/v8/i7/311.htm
- DOI: https://dx.doi.org/10.4239/wjd.v8.i7.311